Patents by Inventor Eui-Joong Kim
Eui-Joong Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240000901Abstract: A polypeptide having superoxide dismutase (SOD) activity and/or extracellular vesicles containing SOD is effective for the prevention and/or treatment of respiratory viral infection or diseases caused by respiratory viral infection in a subject. The polypeptide has SOD activity derived from a Bacillus amyloliquefaciens strain and/or extracellular vesicles containing SOD derived from a Bacillus subtillis strain is useful for the prevention and/or treatment of respiratory viral infection or diseases caused by respiratory viral infection in a subject.Type: ApplicationFiled: November 23, 2021Publication date: January 4, 2024Applicant: GENOFOCUS CO., LTD.Inventors: Jae Gu PAN, Eui Joong KIM, Jeong Hyun KIM
-
Publication number: 20230285517Abstract: The present invention relates, in part, to methods of preventing or treating macular degeneration in a subject by co-administering a superoxide dismutase enzyme and probiotic Bacillus sp. spores, especially a Bacillus amyloliquefaciens GF423 or GF424 mutant strain. The present invention also provides pharmaceutical and/or food compositions comprising a superoxide dismutase enzyme and probiotic Bacillus sp. spores.Type: ApplicationFiled: May 5, 2021Publication date: September 14, 2023Inventors: Jae Gu Pan, Eui Joong Kim, Jeong Hyun Kim, Do Young Yum
-
Publication number: 20220281928Abstract: The present invention relates to a signal sequence for expressing a CRM197 protein in Escherichia coli and secreting same into the periplasm, and a use thereof, and more specifically, to: a signal sequence for expressing a CRM197 protein; a nucleic acid for coding the signal sequence; a nucleic acid construct or expression vector comprising the nucleic acid and a CRM197 protein gene; a recombinant microorganism having the nucleic acid construct or expression vector introduced therein; and a CRM197 protein production method comprising a step for culturing the recombinant microorganism.Type: ApplicationFiled: October 2, 2019Publication date: September 8, 2022Inventors: Jeong Hyun KIM, Hyun-Do KIM, Eun-Hye PARK, Jung Hyun KANG, Jae Gu PAN, Eui Joong KIM, Chankyu LEE, Mimchul PARK
-
Patent number: 11147858Abstract: The present invention relates to a pharmaceutical composition for preventing or treating inflammatory disease, which contains, as an active ingredient, a Bacillus amyloliquefaciens GF423 strain, a superoxide dismutase high-producing Bacillus amyloliquefaciens GF424 mutant strain, a superoxide dismutase (SOD) derived from one of these strains, or both the strain and the SOD. The superoxide dismutase derived from the Bacillus amyloliquefaciens GF423 strain (KCTC 13222BP), which is the active ingredient of the present invention, effectively suppresses or degrades reactive oxygen species, and thus has the effect of fundamentally preventing the causes of inflammatory bowel disease caused by reactive oxygen species. Therefore, the composition of the present invention may be developed into various products, including excellent drugs and health functional foods for preventing or treating inflammatory bowel disease.Type: GrantFiled: December 26, 2018Date of Patent: October 19, 2021Assignee: GENOFOCUS, INC.Inventors: Do Young Yum, Jeong Hyun Kim, Jae Gu Pan, Eui Joong Kim, Ji Eun Kang
-
Publication number: 20200316177Abstract: The present invention relates to a pharmaceutical composition for preventing or treating inflammatory disease, which contains, as an active ingredient, a Bacillus amyloliquefaciens GF423 strain, a superoxide dismutase high-producing Bacillus amyloliquefaciens GF424 mutant strain, a superoxide dismutase (SOD) derived from one of these strains, or both the strain and the SOD. The superoxide dismutase derived from the Bacillus amyloliquefaciens GF423 strain (KCTC 13222BP), which is the active ingredient of the present invention, effectively suppresses or degrades reactive oxygen species, and thus has the effect of fundamentally preventing the causes of inflammatory bowel disease caused by reactive oxygen species. Therefore, the composition of the present invention may be developed into various products, including excellent drugs and health functional foods for preventing or treating inflammatory bowel disease.Type: ApplicationFiled: December 26, 2018Publication date: October 8, 2020Inventors: Do Young YUM, Jeong Hyun KIM, Jae Gu PAN, Eui Joong KIM, Ji Eun KANG
-
Patent number: 10751393Abstract: The present invention relates to a Bacillus amyloliquefaciens strain that produces superoxide dismutase (SOD), and also relates to an antioxidant, anti-inflammatory pharmaceutical composition and a pharmaceutical composition and food composition for preventing or treating hyperlipidemia, which include a superoxide dismutase produced by the Bacillus amyloliquefaciens strain. The compositions of the present invention exhibit excellent effects without causing side effects, and may thus be used as functional raw materials or products having an enhanced activity of preventing or treating inflammation, cancer or hyperlipidemia in the pharmaceutical drug, food, cosmetic and livestock fields.Type: GrantFiled: March 7, 2018Date of Patent: August 25, 2020Assignee: GENOFOCUS INC.Inventors: Do Young Yum, Jeong Hyun Kim, Jae Gu Pan, Eui Joong Kim, Taek Ho Yang, Ji Eun Kang, Soo Young Park, Hyun Do Kim
-
Patent number: 10526592Abstract: The present invention relates to a beta-galactosidase mutant having high transglycosylation activity and containing a C-terminal deletion, and the use thereof and more. More specifically, the present invention relates to a beta-galactosidase mutant having a C-terminal deletion, a gene encoding the same, a recombinant vector containing the gene, a recombinant microorganism transformed with the gene or the recombinant vector, and a method for producing the beta-galactosidase mutant using the recombinant microorganism. Using the high transglycosylation activity of the beta-galactosidase mutant containing the C-terminal deletion according to the present invention, galactooligosaccharide can be efficiently produced in large amounts.Type: GrantFiled: May 19, 2016Date of Patent: January 7, 2020Assignee: GENOFOCUS CO., LTD.Inventors: Su Jin Kim, Young-Jae Eu, Taek Ho Yang, Jae Gu Pan, Eui Joong Kim
-
Publication number: 20190343928Abstract: The present invention relates to a Bacillus amyloliquefaciens strain that produces superoxide dismutase (SOD), and also relates to an antioxidant, anti-inflammatory pharmaceutical composition and a pharmaceutical composition and food composition for preventing or treating hyperlipidemia, which include a superoxide dismutase produced by the Bacillus amyloliquefaciens strain. The compositions of the present invention exhibit excellent effects without causing side effects, and may thus be used as functional raw materials or products having an enhanced activity of preventing or treating inflammation, cancer or hyperlipidemia in the pharmaceutical drug, food, cosmetic and livestock fields.Type: ApplicationFiled: March 7, 2018Publication date: November 14, 2019Inventors: Do Young YUM, Jeong Hyun KIM, Jae Gu PAN, Eui Joong KIM, Taek Ho YANG, Ji Eun KANG, Soo Young PARK, Hyun Do KIM
-
Patent number: 10472616Abstract: The present invention relates to a novel alpha-1,3-glucanase, and more particularly, to a novel alpha-1,3-glucanase from Trichoderma harzianum, a gene encoding the same, a recombinant vector and recombinant microorganism comprising the gene, and a method of producing an alpha-1,3-glucanase using the recombinant microorganism. The novel alpha-1,3-glucanase according to the present invention can effectively degrade mutan, which is a component of a microbial biofilm, and thus it can be used in oral hygiene products and the medical field.Type: GrantFiled: July 15, 2016Date of Patent: November 12, 2019Assignee: GENOFOCUS CO., LTD.Inventors: Jae Gu Pan, Eui Joong Kim, Taek Ho Yang, Dong Beom Lee, Eun Young Kim, Hye Rim Lee, Jung Hyun Kang
-
Publication number: 20190192258Abstract: Disclosed is a stepwise automatic orthodontic system and method using an artificial intelligence technique. The method includes: scanning a dental state of a patient by using an intraoral scanner; allowing a server to determine to which group of grouped data of the database the scanned dental data belong; allowing the server to refer to data of the determined group, move a tooth needing orthodontics gradually, and generate a predictive digital orthodontic dental data set; allowing the server to transmit the orthodontic-processed digital orthodontic dental data set of a patient to a 3D printer, and allowing the 3D printer to generate and output a dental orthodontic model; and generating a clear aligner by vacuum-compressing a transparent synthetic resin plate to the generated dental orthodontic model through a vacuum former.Type: ApplicationFiled: March 13, 2018Publication date: June 27, 2019Inventors: Je Hun KANG, Kweon Seok KANG, Eui Joong KIM
-
Patent number: 10036000Abstract: The present invention relates to a novel beta-galactosidase, and more particularly to a novel beta-galactosidase derived from Bacillus circulans, a gene encoding the beta-galactosidase, a recombinant vector and a recombinant microorganism, which contain the gene, a method for producing a beta-galactosidase using the recombinant microorganism, and a method for producing galactooligosaccharide using the beta-galactosidase. The use of the novel beta-galactosidase according to the present invention makes it possible to efficiently produce a large amount of galactooligosaccharide.Type: GrantFiled: May 19, 2015Date of Patent: July 31, 2018Assignee: GENOFOCUS CO., LTD.Inventors: Jae Youl Choi, Jae Gu Pan, Seung Hwan Park, Eui Joong Kim
-
Publication number: 20180201914Abstract: The present invention relates to a novel alpha-1,3-glucanase, and more particularly, to a novel alpha-1,3-glucanase from Trichoderma harzianum, a gene encoding the same, a recombinant vector and recombinant microorganism comprising the gene, and a method of producing an alpha-1,3-glucanase using the recombinant microorganism. The novel alpha-1,3-glucanase according to the present invention can effectively degrade mutan, which is a component of a microbial biofilm, and thus it can be used in oral hygiene products and the medical field.Type: ApplicationFiled: July 15, 2016Publication date: July 19, 2018Inventors: Jae Gu Pan, Eui Joong Kim, Taek Ho Yang, Dong Beom Lee, Eun Young Kim, Hye Rim Lee, Jung Hyun Kang
-
Publication number: 20180155699Abstract: The present invention relates to a beta-galactosidase mutant having high transglycosylation activity and containing a C-terminal deletion, and the use thereof and more. More specifically, the present invention relates to a beta-galactosidase mutant having a C-terminal deletion, a gene encoding the same, a recombinant vector containing the gene, a recombinant microorganism transformed with the gene or the recombinant vector, and a method for producing the beta-galactosidase mutant using the recombinant microorganism. Using the high transglycosylation activity of the beta-galactosidase mutant containing the C-terminal deletion according to the present invention, galactooligosaccharide can be efficiently produced in large amounts.Type: ApplicationFiled: May 19, 2016Publication date: June 7, 2018Applicant: GENOFOCUS CO., LTD.Inventors: Su Jin Kim, Young-Jae Eu, Taek Ho Yang, Jae Gu Pan, Eui Joong Kim
-
Publication number: 20170198271Abstract: The present invention relates to a novel beta-galactosidase, and more particularly to a novel beta-galactosidase derived from Bacillus circulans, a gene encoding the beta-galactosidase, a recombinant vector and a recombinant microorganism, which contain the gene, a method for producing a beta-galactosidase using the recombinant microorganism, and a method for producing galactooligosaccharide using the beta-galactosidase. The use of the novel beta-galactosidase according to the present invention makes it possible to efficiently produce a large amount of galactooligosaccharide.Type: ApplicationFiled: May 19, 2015Publication date: July 13, 2017Inventors: Jae Youl Choi, Jae Gu Pan, Seung Hwan Park, Eui Joong Kim
-
Publication number: 20160274706Abstract: A touch sensor for a curved display includes: a first sensor including a) first sensor patterns arranged on a first flexible plastic substrate so as to be continuous in a first direction and spaced apart from each other by a predetermined interval in a second direction and b) first dummy patterns arranged between the first sensor patterns on the first flexible plastic substrate; a second sensor including a) second sensor patterns arranged on a second flexible plastic substrate so as to be continuous in the second direction and be spaced apart from each other by a predetermined interval in the first direction and b) second dummy patterns arranged between the second sensor patterns on the second flexible plastic substrate; and an adhering part causing the first sensor and the second sensor to adhere to each other.Type: ApplicationFiled: June 28, 2015Publication date: September 22, 2016Inventors: Kyoung Chun Kweon, Ji Hun Park, Seong Hwan Lim, Eui Joong Kim, Ho Seop Song
-
Patent number: 8669078Abstract: Disclosed herein are ammonia-specific 5?-XMP aminase mutants and a method for preparing the same. A mutation is introduced into the active site of glutamine-dependent catalysis in 5?-XMP aminase. The resulting 5?-XMP aminase mutant is devoid of the glutamine-dependent activity and specifically reacts with external ammonia in converting 5?-XMP into 5?-GMP. Thus, the ammonia-specific 5?-XMP aminase mutant is stabler within cells compared to the wild type, and can be useful in the industrial conversion of 5?-XMP into 5?-GMP.Type: GrantFiled: December 14, 2006Date of Patent: March 11, 2014Assignee: CJ Cheiljedang CorporationInventors: Jae-Gu Pan, Heung-Chae Jung, Eui-Joong Kim, Han-Seung Lee, Young Hoon Park, Hyoung Suk Kim, Jong-Kwon Han, Jin Nam Lee, Ki-Hoon Oh, Jeong Hwan Kim, Yoon-Suk Oh, Jae Ick Sim, Kuk-Ki Hong, Kyung Oh Choi, Hyun Soo Kim, Min-Ji Baek, Tae Sun Kang
-
Patent number: 7576926Abstract: A spill light removing device includes a first blocker which is located perpendicularly to a stream route of light being irradiated from a light source and blocks a stream of light that is incident to the surface of the first blocker, except on a hole formed on the first blocker; a pass-through tunnel which is connected to the hole and is formed in the same direction to the stream route of light and allows the stream of the light to pass through; and a second blocker which has a irregularity pattern that is formed on a inner wall of the pass-through tunnel and reflects the light that is incident in the deviated direction of the stream route of light.Type: GrantFiled: June 9, 2008Date of Patent: August 18, 2009Assignee: Samsung Electro-Mechanics Co., Ltd.Inventors: Sung-Ho Byun, Haeng-Seok Yang, Sung-Kyong Oh, Eui-Joong Kim, Byoung-Ki Song, Koan-Young Oh
-
Publication number: 20090009849Abstract: A spill light removing device includes a first blocker which is located perpendicularly to a stream route of light being irradiated from a light source and blocks a stream of light that is incident to the surface of the first blocker, except on a hole formed on the first blocker; a pass-through tunnel which is connected to the hole and is formed in the same direction to the stream route of light and allows the stream of the light to pass through; and a second blocker which has a irregularity pattern that is formed on a inner wall of the pass-through tunnel and reflects the light that is incident in the deviated direction of the stream route of light.Type: ApplicationFiled: June 9, 2008Publication date: January 8, 2009Applicant: SAMSUNG ELECTRO-MECHANICS CO., LTD.Inventors: Sung-Ho Byun, Haeng-Seok Yang, Sung-Kyong Oh, Eui-Joong Kim, Byoung-Ki Song, Koan-Young Oh
-
Publication number: 20090002640Abstract: A display device includes a red laser light source which irradiates light in wavelength range of 636 nm to 645 nm; and a light projector which modulates and project the light on screen. With a display device according to embodiments of the present disclosure, the projected image may be by using three laser light sources which irradiate red, green and blue light each of which wavelengths is limited to 636 nm to 645 nm, 520 nm to 532 nm or 430 nm to 454 nm.Type: ApplicationFiled: June 27, 2008Publication date: January 1, 2009Applicant: Samsung Electro-Mechanics Co., Ltd.Inventors: Haeng-Seok Yang, Sung-Kyong Oh, Eui-Joong Kim, Byoung-Ki Song, Joo-Hong Kim, Sung-Ho Byun
-
Publication number: 20080318278Abstract: Disclosed herein are ammonia-specific 5?-XMP aminase mutants and a method for preparing the same. A mutation is introduced into the active site of glutamine-dependent catalysis in 5?-XMP aminase. The resulting 5?-XMP aminase mutant is devoid of the glutamine-dependent activity and specifically reacts with external ammonia in converting 5?-XMP into 5?-GMP. Thus, the ammonia-specific 5?-XMP aminase mutant is stabler within cells compared to the wild type, and can be useful in the industrial conversion of 5?-XMP into 5?-GMP.Type: ApplicationFiled: December 14, 2006Publication date: December 25, 2008Applicant: CJ CHEILJEDANG CORPORATIONInventors: Jae-Gu Pan, Heung-Chae Jung, Eui-Joong Kim, Han-Seung Lee, Young Hoon Park, Hyoung Suk Kim, Jong-Kwon Han, Jin Nam Lee, Ki-Hoon Oh, Jeong Hwan Kim, Yoon-Suk Oh, Jae Ick Sim, Kuk-Ki Hong, Kyung Oh Choi, Hyun Soo Kim, Min-Ji Baek, Tae Sun Kang